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Background: Although athletes have a high prevalence of airway hyperresponsiveness (AHR)
and asthma, little is known about possible gender differences in regard to these features.
We looked at the comparative prevalence of AHR, physician-diagnosed asthma and respiratory
symptoms during exercise in female (F) and male (M) athletes.
Method: A retrospective analysis was done on 2 groups of athletes: Group 1 (nZ 100) taking
part in a study on the prevalence of AHR to methacholine (PC20< 16 mg/ml) and Group 2
(nZ 698), taking part in a provincial survey on the prevalence of physician-diagnosed asthma.
Subjects from both groups filled the same questionnaire on respiratory symptoms during exer-
cise (breathlessness, wheezing and chest tightness).
Results: In Group 1, prevalence of AHR was significantly higher in female (60%) compared with
male (21.5%, p< 0.0001) athletes despite a similar prevalence of physician-diagnosed asthma
(F: 17.1%, M: 15.4%, p> 0.05). Respiratory symptoms during exercise were more frequently re-
ported in females (37.1%, M: 16.9%, pZ 0.02); however, when corrected for the PC20, this differ-
ence became non-significant. In Group 2, the prevalence of physician-diagnosed asthmawas not
different between genders (F: 12.5%, M: 14%, p> 0.05) but respiratory symptoms during exercise
were more often reported in female (19.4%) than in male (12.2%, pZ 0.01) athletes.
Conclusions: This analysis shows a higher prevalence of AHR and exercise-induced respiratory
symptoms in female compared tomale athletes, but a similar prevalence of physician-diagnosed
asthma. This suggested that the increase in respiratory symptoms in female athletes failed to
translate into a higher prevalence of physician-diagnosed asthma.
ª 2008 Elsevier Ltd. All rights reserved.2725, Chemin Sainte-Foy, Que´bec, Canada, GlV 4G5.
l, 2725 Chemin Sainte-Foy, Que´bec, Canada, GlV 4G5. Tel.: þ1 418 656 4747; fax: þ1 418 656 4762.
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A high prevalence of airway hyperresponsiveness (AHR) and
asthma have been reported in athletes.1,2 In a previous
study,3 we looked at the prevalence of AHR in athletes,
categorized according to the type of air predominantly
inhaled during training (Dry, Cold, Humid, and Mixture of
dry/humid Air). We observed a higher prevalence of AHR in
athletes than in sedentary subjects, mainly explained by
the surprisingly high prevalence in swimmers, and to
a lesser extent, in athletes training in cold air. Later, we
conducted a survey in another population of athletes
looking at the prevalence of physician-diagnosed asthma
and respiratory symptoms associated with exercise through
a self-administrated questionnaire.4,5 We found that the
prevalence of asthma was similar in the various groups of
athletes, whatever the type of air predominantly inhaled
during training. However, for those two studies, the
contribution of gender for those specific outcomes was not
evaluated.
For the general population, there is evidence suggesting
that AHR is more prevalent in women than in men.6,7
Furthermore, many authors have reported that the rate of
emergency visits, hospitalizations, and health care utiliza-
tion for asthma are higher in females than males.8e11 From
a longitudinal population-based study of asthmatic subjects
followed from childhood to adulthood, Sears et al. found
that female gender was a predictor of persistence of
wheezing at age 21.12 However, when it comes to the
diagnosis of asthma, the distinction between genders
appears less clear.
While gender differences in the prevalence and clinical
expression of airway diseases are receiving increasing
attention, little is known about such differences in
athletes. As we wondered if the reported prevalence of
AHR, physician-diagnosed asthma and exercise-induced
respiratory symptoms from the two previously described
populations of athletes could be different according to
gender, we therefore undertook a sub-analysis of those two
studies with the objective of comparing gender differences
in athletes for the above-mentioned respiratory outcomes.
Methods
Study design and subjects
The two studies that were used for this sub-analysis
included data from two different athlete populations. In
the first study (Group 1),3 the main objective was to
measure the prevalence of AHR, but prevalence of physi-
cian-diagnosed asthma and respiratory symptoms with
exercise was also documented; this was determined using
a questionnaire administered to 100 athletes distributed in
7 sports disciplines according to the type of air inhaled
during training, and 50 sedentary subjects. In the second
study (Group 2),4 data were obtained from a survey ques-
tionnaire sent to all registered athletes of the Province of
Quebec (Canada); the main objective was to evaluate the
prevalence of physician-diagnosed asthma (PDA) and
respiratory symptoms associated with exercise (exercise-
induced respiratory symptoms: EIRS) in athletes from 33sports disciplines; all disciplines not involving a significant
stress on the respiratory system, such as shooting, archery,
equestrian, etc., were not selected for the survey ques-
tionnaire. For both studies, the complete lists of the sport
disciplines in which recruited athletes were involved have
already been enumerated in our previous studies.3,4 The
local institutional ethics committee approved those two
study protocols.
In Group 1, the athletes were administered an ‘‘on site’’
questionnaire by one of the two research coordinators (JBL,
HT), and underwent a methacholine challenge to assess
airway responsiveness as quantified by the provocative
concentration of methacholine inducing a 20% fall in Forced
Expiratory Volume in one second (PC20 FEV1). AHR was
defined as a PC20< 16 mg/ml. A skin prick test was also
performed in these subjects with a battery of 26 common
allergens, including animal danders, housedust mite,
pollens and molds. Subjects were considered atopic if they
had at least one positive response to allergy skin prick
tests, as shown by a mean weal diameter of 3 mm at
10 min. To be included in Group 1, athletes had to be
members of a recognized Provincial Sports Federation and
aged from 18 to e55-years-old. In Group 2, a total of 1468
athletes, all members of a recognized Provincial Sports
Federation, were sent a ‘‘self-administration’’ question-
naire accompanied by a letter from their respective Sport
Federation inviting them to participate in the study; 698
athletes responded with a valid questionnaire (response
rate: 47.6%). Responders from Group 2 were included
without restriction of age limit or smoking status.
From both questionnaires (in French for both Groups),
we extracted the following characteristics: gender, age,
physician-diagnosed asthma (PDA) and exercise-induced
respiratory symptoms (EIRS). Questions to determine PDA
and EIRS were respectively formulated as followed: ‘‘Have
you ever been told by your doctor that you have asthma?’’
and ‘‘When you exercise, do you feel respiratory symptoms
such as breathlessness, chest tightness or wheeze?’’.
Subjects were considered having PDA or EIRS if they
respectively answered ‘‘yes’’ to these questions. These two
questions have not been formally validated but were
adapted from other questionnaires.13 Questionnaire for
Group 2, included an additional question in order estimate
atopy and was formulated as followed: ‘‘Have you ever
been tested for allergies? If yes, to which of the following
were you allergic to: mites, dust mites, grass, ragweed,
trees, animal or any others (please name them)’’; atopy
was considered to be present if subjects reported having
tested positive of at least one allergen.Statistical analysis
Results were expressed as mean SD and percent for
categorical variables. The analyses of continuous variables
were performed using Student’s t-test. The normality
assumption was verified with the Shapiro-Wilk test, and
Bartlett’s statistic was used to verify the homogeneity of
variances. Categorical variables were analyzed using Fish-
er’s exact test. Results were considered significant if p-
values were 0.05. Data were analyzed using the statistical
package SAS v9.1.3 (SAS Institute Inc., Cary, NC).
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Figure 1 Gender differences in prevalence of AHR at various
cut-off values of PC20.
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Subject characteristics
Group 1 included a larger number of male athletes (65% vs
35% for female), with the male being older than the female
athletes. The number of hours per week spent in training,
as well as the numbers of years of involvement in their
respective sports discipline, was similar for both genders.
As a point of comparison to a non-athlete population, we
have also included the characteristics of the control group
of sedentary subjects (Table 1). Among athletes of Group 2,
45% were males and 55% females. There were no significantTable 1 Subjects characteristics.
Group 1
Athletes F M
Number of subjects 100 35 65
Mean age (SD) 24.9 (8.4) 21.2 (2.8)y 26.8 (9.7)
Hours/week training in
respective discipline (SD)
15.9
(5.8)
16.2
(5.7)
15.7
(5.8)
Years of training in
respective discipline (SD)
8.7
(5.5)
8.1
(4.7)
9.1
(6.0)
Exercise-induced
respiratory symptoms
24% 37.1%* 16.9%
Physician-diagnosed asthma 16% 17.1% 15.4%
Atopy 76% 62.9%* 83.1%
FEV1, L (SD) 4.2
(0.7)
3.7
(0.6)
4.5
(0.6)
FEV1, % predicted (SD) 109.6
(12.5)
111.8
(12.4)
108.4
(12.4)
PC20 mg/ml,
geometric mean
16.5 6.7z 27.1
PC20 mg/ml, (95% CI) (11.0, 22.2) (3.7, 12.2) (16.4, 40.5
F: female, M: male, SD: standard deviation, CI: confidence interval.
e Data not available, *p< 0.05 compare with male, yp< 0.001 compa
Atopy was determined by skin prick test (in Group 1), and by self-admgender differences for age, hours/week spent in training,
or numbers of years involved in their respective sports
disciplines (Table 1).
Prevalence of airway hyperresponsiveness
Methacholine challenge testing was performed in Group 1
only. The mean PC20 to methacholine was significantly
lower in female athletes (pZ 0.0001, Table 1). There was
a significantly higher proportion of women athletes with
AHR compared to men, and this, at all cut-off PC20 values
(<2, <4, <8 and <16 mg/ml, all p< 0.05, Fig. 1).
However, among the control group composed of sedentary
subjects (nZ 50) there were no gender differences for the
prevalence of AHR at all cut-off PC20 values; F vs M were
respectively, 32% vs 24% (at <16 mg/ml), 20% vs 16% (at
<8 mg/ml), 12% vs 8% (at <4 mg/ml), and 0% vs 0% (at
<2 mg/ml, all p> 0.05, Fig. 1). When the prevalence of
AHR was compared between F athletes and F controls,
these prevalences were significantly higher in F athletes at
all cut-off PC20 values (respectively, <4 mg/ml
(pZ 0.022), <8 mg/ml (pZ 0.003), and <16 mg/ml
(pZ 0.018)). In M athletes, however, these prevalences
were not significantly different than the M controls (all
p> 0.05, Fig. 1).
Prevalence of physician-diagnosed asthma
Based on our criteria for PDA, there were no significant
differences in the prevalence of PDA between males and
females, in either group (Table 1). Among the 50 sedentary
subjects, there was also no difference in prevalence of PDA
between women and men; 1/25 vs 0/25 (p> 0.05).Group 2
Controls F M Athletes F M
50 25 25 698 384 314
26.8 (7.8) 27.0 (8.4) 26.6 (7.3) 19.0
(4.0)
18.7
(3.7)
19.4
(4.2)
e e e 14.7
(7.6)
14.4
(8.0)
15.0
(7.0)
e e e 8.8
(4.0)
8.7
(4.1)
9.0
(4.0)
e e e 16.2% 19.4%* 12.2%
2% 4% 0% 13.2% 12.5% 14%
82% 76% 88% 20.5% 19.3% 22.0%
3.9
(0.7)
3.3
(0.5)
4.4
(0.5)
e e e
104.7
(10.4)
106.6
(12.1)
102.7
(8.1)
e e e
36.6 27.1 44.7 e e e
) (24.5, 54.6) (16.5, 49.4) (27.1, 73.7) e e e
re with male, zp< 0.0001 compare with male.
inistrated questionnaire (in Group 2).
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symptoms
In both groups, the prevalence of reported EIRS was
significantly higher in F athletes compared to M athletes
(Table 1). In Group 1, however, although EIRS were more
frequently reported in F athletes, this difference became
non-significant when adjusted for PC20.
Prevalence of asymptomatic airway
hyperresponsiveness
In Group 1, the proportion of athletes showing asymptom-
atic AHR, as estimated by the absence of EIRS in presence
of a positive PC20 (at different cut-off values: <4, <8, and
<16 mg/ml), was similar between F and M athletes; 43% vs
44% (at <4 mg/ml), 52% vs 64% (at <8 mg/ml), and 52% vs
65% (at <16 mg/ml), respectively (p> 0.05) (Table 2).
Prevalence of atopy
In Group 1, the prevalence of atopy, as determined by
a positive skin prick test, was significantly higher in M than
F athletes. This was not the case in Group 2, where the
percentages of subjects reporting at least one positive
result were similar for both gender (Table 1).
Discussion
This analysis demonstrates that female athletes show
a significantly higher prevalence of AHR compared to male
athletes. This gender difference for AHR seems unique to
the athlete population, as there was no gender differences
in AHR, for all cut-off values (<2, <4, <8 or <16 mg/ml) in
the control group composed of sedentary subjects (from
Group 1). This suggests that within our athlete population,Table 2 Contingency tables for various AHR and EIRS.
Female
EIRS no EIRS Total
PC20 4
AHR 8 (57) 6 (43) 14
no AHR 5 (24) 16 (76) 21
Total 13 22 35
pZ N
PC20 8
AHR 10 (48) 11 (52) 21
no AHR 3 (21) 11 (79) 14
Total 13 22 35
pZ N
PC20 16
AHR 11 (48) 12 (52) 23
no AHR 2 (17) 10 (83) 12
Total 13 22 35
pZ N
Numbers in parenthesis represent percentage (%).
Statistical signifiance were defined per a Chi-square p-value of less tthere are unidentified factors that contribute to the higher
prevalence of AHR in women.
Interestingly, the analysis of Group 1 indicates that,
despite the fact that female athletes had a higher degree of
AHR (i.e. lower PC20 value) and reported more respiratory
symptoms during exercise (EIRS) compared to male
athletes, the prevalence of PDA remained similar for both
genders. This dissociation between exercise-induced
symptoms and asthma diagnosis was also found in Group 2.
The discrepancy between AHR and PDA in athletes has
previously been suggested to be due to an under-diagnosis
of asthma as a possible result of under-reporting of respi-
ratory symptoms and/or a reduction in perception of such
symptoms.14 This analysis, however, appears to indicate
that women athletes are aware of the presence of exercise-
induced respiratory symptoms and that these symptoms are
associated with a higher degree of airway responsiveness.
Although the dissociation between AHR and PDA has
already been suggested in athletes,14 this analysis shows
that the degree of discrepancy between AHR and PDA
according to gender is more marked in female compared to
male athletes. Higher prevalence of asymptomatic AHR in
female athletes could have been one possible explanation,
however, our analysis indicates that the proportion of
asymptomatic AHR, regardless of the cut-off values used for
PC20 to methacholine, was similar for both gender.
Furthermore, asymptomatic AHR was numerically higher in
males than in females. This suggests that the higher prev-
alence of AHR in female athletes were not attributable to
a greater proportion of asymptomatic subjects.
We previously reported that prevalence of AHR was
increased in swimmers and in athletes training in cold air.3
Consequently, one of these two categories of athletes could
have contributed to the higher prevalence of AHR in female
athletes. However, when gender differences for AHR (at
<2, <4, <8 or 16 mg/ml) were adjusted for the 4 categories
of athletes (determined by the type of air predominantlyMale
EIRS no EIRS Total
5 (56) 4 (44) 9
6 (11) 50 (89) 56
11 54 65
.S. pZ 0.001
5 (36) 9 (64) 14
6 (12) 45 (88) 56
11 54 65
.S. pZ 0.03
9 (35) 17 (65) 26
2 (5) 37 (95) 39
11 54 65
.S. pZ 0.002
han 0.05.
Gender differences in athletes 405inhaled during training), the observed gender differences in
AHR remained statistically higher in female athletes. Also,
age and body mass index did not explain this difference;
when adjusting for these two factors, gender differences in
AHR still remained.
A greater response to methacholine due to smaller
airway caliber could have been a possible contributor to
a higher prevalence of AHR in female athletes. In this
regard, Laynaert et al. concluded from a general pop-
ulation-based sample composed of 20e44 yrs old subjects,
that the higher prevalence of AHR to methacholine
observed in women compared to men could not be
explained by a higher prevalence of respiratory symptoms
among women, as the difference in AHR between male and
female was greater among asymptomatic than symptomatic
subjects.7 Furthermore, using various logistic regression
methods to adjust for airway caliber and lung size, he
documented that the higher prevalence of AHR in women
was not due to smaller lung size and airway caliber but
possibly related to smoking status. Compared to Laynaert
et al. however, we assessed only respiratory symptoms
associated with exercise.
In Group 1, it is possible that the higher degree of airway
responsiveness in female athletes, compared to males, was
attributable to other physiological factors than difference
in airway caliber, such as hormonal influences. It has been
previously reported, among female athletes and non-
athletes, that menstrual cycle was associated with airway
changes.15,16 Unfortunately, in our study (Group 1), infor-
mation pertaining to menstrual cycle was not documented.
In Groups 1 and 2, prevalence of PDA was similar for both
genders. Still, when adjusting for the 4 categories of
athletes according to the type of air predominantly inhaled
during training, the proportion of PDA remained similar
between male and female athletes. This absence in gender
difference for PDA is consistent with what is observed in the
general population. Many studies have identified that the
rate of PDA, as well as asthma severity for females were
similar to those of men.10,11 We may expect that such
similar prevalences of PDA would correlate with the report
of respiratory symptoms for both genders. However, that
was not the case between the two populations of athletes
that we studied. In female athletes from both groups,
a significant discrepancy observed between PDA and exer-
cise-induced respiratory symptoms indicating that female
athletes either had more respiratory symptoms than male
athletes, or had a greater perception and/or better
recognition of these symptoms. Again, when adjusting for
the 4 categories of athletes according to the type of air
predominantly inhaled during training, it did not explain
the higher prevalence of EIRS in female athletes. Never-
theless, this increased prevalence of symptoms did not
translate into an increased prevalence of PDA in female
athletes. The cause of this larger gap between perception
of respiratory symptoms to exercise and diagnosis of
asthma in female athletes has not being identified and is
likely multifactorial. It might be that female, compared to
male athletes, under-report respiratory symptoms related
with exercise and/or less frequently consult a physician for
these symptoms. Female athletes may have a greater
temporal adaptation to nociceptive stimuli than male
athletes. Equally, it is also possible that female athletesinterpret their symptoms differently than males, and tend
to consider as normal the presence of symptoms during
exercise. On the other hand, it is also possible female
athletes perceive, to a greater extent than male, the
presence of respiratory symptoms, or the reporting of these
symptoms, as a sign of weakness or an indication of
potential limitation on their performance development,
and consequently decide to ignore them.
Female athletes may manage their respiratory symptoms
differently than females from the general population.
Manfreda et al. found that the presence of asthma symp-
toms and exacerbations were higher in women than in men
in the Canadian population.17 Later on, Day et al. also
found through a nationwide survey of Canadian asthmatic
individuals that, despite a similar level of poorly controlled
asthma among both women and men, women were more
likely to report limitations of physical activities, absen-
teeism, and exacerbations.11 Furthermore, women were
also more inclined to use health care resources such as
emergency care and unscheduled visits to a physicians for
their asthma. Likewise, Schatz et al. have documented
from a pool of 30 US hospitals, that despite the observation
that female had an asthma history and medication usage
similar to those of men, they were more likely to have
a primary care provider.18 In contrast, our female athletes
appear to consult a physician for respiratory symptoms less
frequently than female from the general population. It is
also possible that physicians tend to underestimate short-
ness of breath on exertion in women athletes because of
diagnostic bias. Consequently, perhaps a more systematic
use of objective measures for airway limitations in athletes
presenting with respiratory symptoms could be a valuable
addition to help determine the appropriate diagnosis. Doing
so, Schoene et al. found a greater proportion of female
track athletes (26%) presented a 10% decrease in peak
expiratory flows compared with male track athletes
(10%).19
In Group 1, as atopy was objectively measured by skin
prick test in those athletes, the overall prevalence (76%)
was higher that the one subjectively assessed by ques-
tionnaires in athletes of Group 2 (20.5%). When comparing
for gender differences, regardless of the method used to
document atopy, the prevalences were not higher in female
athletes compare with male athletes.
Possible limitations for the two original studies (Group 1
and 2) have previously been described3e5,20; however, for
the present sub-analysis it is worth highlighting some
additional elements. It could be argued that it would have
been more relevant to study gender differences in regard to
the correlation between exercise-induced bronchocon-
striction (EIB) and EIRS. Unfortunately, data on EIB were
not collected, being difficult to establish through a ques-
tionnaire survey, especially in Group 2 where participants
were not evaluated on site. In the present analysis, we
chose as criteria of EIRS in athletes the recognition of one
or more of 3 symptoms: breathlessness, wheezing and chest
tightness. We did not analyze each of those symptoms
separately as our objective was rather to establish if there
was an overall trend of difference in the perception of
respiratory symptoms between male and female athletes.
In this present study, no analysis of asthma medication was
performed; medications use has already been reported in
406 J.-B. Langdeau et al.our previous studies and was minimal, mostly in the form of
a short-acting beta2-agonist on demand.4,5,20
This analysis shows that, in athletes, AHR is significantly
higher in females compared to males, that respiratory
symptoms during exercise are more frequently reported in
females, that this difference is in keeping with their degree
of airway responsiveness, and finally, that the higher prev-
alence of respiratory symptoms in females does not translate
into a greater prevalence of physician-diagnosed asthma.
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